Dr Kin on Clinical Implications of the FDA Approval of Teclistamab in ...
OncLive - 23 May 2023Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.
Multiple myeloma
Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Nature - 09 May 2025Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium ...
Multiple Myeloma: Improved Prognosis With the Latest Treatments
Memorial Sloan Kettering Cancer Center - 13 Feb 2025Multiple Myeloma: Improved Prognosis With the Latest Treatments ...
Advances in Multiple Myeloma Research - NCI
National Cancer Institute (.gov) - 06 Mar 2025Advances in Multiple Myeloma Research - NCI ...
The Price of Remission
ProPublica - 08 May 2025The Price of Remission ...
Multiple myeloma is treatable, not curable. Is that set to change?
Fred Hutchinson Cancer Center - 03 Apr 2025Multiple myeloma is treatable, not curable. Is that set to change? ...
AIIMS, Delhi developing low cost adaptive cellular therapy for treatment of multiple myeloma
The Hindu - 23 Dec 2024AIIMS, Delhi developing low cost adaptive cellular therapy for treatment of multiple myeloma ...
Cilta-cel: A new era in multiple myeloma treatment
Drug Target Review - 29 Jan 2025Cilta-cel: A new era in multiple myeloma treatment ...
Glenmark's research arm gets USFDA fast track status for new drug to treat multiple Myeloma
Business Today - 05 May 2025Glenmark's research arm gets USFDA fast track status for new drug to treat multiple Myeloma ...
Life Has Many Turns for Multiple Myeloma Survivor and Avid Bicyclist Ben Freund
Yale School of Medicine - 08 May 2025Life Has Many Turns for Multiple Myeloma Survivor and Avid Bicyclist Ben Freund ...
Smoldering multiple myeloma: What it is, how it progresses and the latest research
Mayo Clinic News Network - 22 Apr 2025Smoldering multiple myeloma: What it is, how it progresses and the latest research ...
Multiple Myeloma Treatment: The Price of Success
Managed Healthcare Executive - 05 May 2025Multiple Myeloma Treatment: The Price of Success ...
Advancing Multiple Myeloma Treatment
Cleveland Clinic - 27 Mar 2025Advancing Multiple Myeloma Treatment ...
Addressing Unmet Needs in Multiple Myeloma Research
Sanofi - 27 Nov 2024Addressing Unmet Needs in Multiple Myeloma Research ...
Bloodlines Series: Risk, Regimens, and Research for Multiple Myeloma
American Association for Cancer Research (AACR) - 12 Mar 2025Bloodlines Series: Risk, Regimens, and Research for Multiple Myeloma ...
High-risk multiple myeloma treated with CAR T-cell therapy
Healthcare Radius - 15 Dec 2024High-risk multiple myeloma treated with CAR T-cell therapy ...
Trends and projections of the global and regional burden of multiple myeloma in adults aged 40 and over, 1990–2044
Nature - 19 Apr 2025Trends and projections of the global and regional burden of multiple myeloma in adults aged 40 and over, 1990–2044 ...
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes | Blood Cancer Journal
Nature - 04 Apr 2025Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes | Blood Cancer Journal ...
PCMMD: A Novel Dataset of Plasma Cells to Support the Diagnosis of Multiple Myeloma
Nature - 27 Jan 2025PCMMD: A Novel Dataset of Plasma Cells to Support the Diagnosis of Multiple Myeloma ...
A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
Nature - 16 Jan 2025A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast ...